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Antipsychotic drugs: is more worse? A meta-analysis
of the published randomized control trials
P. BOLLINI,1 S. PAMPALLONA, M. J. ORZA, M. E. ADAMS AND T. C. CHALMERS
From the Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
SYNOPSIS Effectiveness and side-effects of high- versus low-dose neuroleptic treatment of chronic
psychosis have been assessed through a meta-analysis of 22 published randomized control trials
comparing different neuroleptic doses. No incremental clinical improvement was found at doses
above 375 mg equivalent of chlorpromazine, while a significant increase in adverse reactions was
observed.
INTRODUCTION
Neuroleptic (NL) medications, also called anti-
psychotics, are widely used in clinical practice to
treat the symptoms of psychosis and other
severe mental disorders. Their primary beneficial
effect is the reduction of positive symptoms of
psychosis (e.g. delusions, hallucinations, bizarre
behaviour, etc.). However, their effectiveness in
controlling negative symptoms (e.g. withdrawal,
blunted affect, psychomotor retardation, etc.)
has been questioned. Because of the occurrence
of adverse reactions, which can be severe and
impair patients' social functioning, the balance
between the benefits and risks of neuroleptic
treatment is extremely delicate (Baldessarini,
1985).
Concern about adverse reactions, in particular
tardive dyskinesia (involuntary movements of
oral and limb muscles, often irreversible, for
which no cure has been found), coupled with the
apparent diminished effectiveness for negative
symptoms characteristic of chronic psychosis,
have raised questions about the appropriateness
of long-term maintenance with NL drugs.
Furthermore, the most appropriate dose of NL
drugs administered as maintenance treatment
has been debated for several years (see for
example Gardos & Cole, 1973; Anderson &
Kuehnle, 1976; Baldessarini et al. 1976; Eriksen
et al. 1976; Aubree & Lader, 1980; Baldessarini
& Davis, 1980; Kane et al. 1986; Baldessarini
et al. 1988).
' Address for correspondence: Dr Paola Bollini, I.O.M., 17 Route
des Morillons, 1211 Geneva, Switzerland.
A few years after the discovery of the
usefulness of the first NL (chlorpromazine) in
psychiatric patients, a wide range of doses were
explored in clinical practice, from 200 mg daily
in the first trial (Delay & Deniker, 1952) up to
4000 mg in subsequent trials (Aubree, 1979).
The justification for high doses was ill-defined,
but, nonetheless, treatment with high doses
became widespread. Largely based on uncon-
trolled studies, high-dose NL treatment was
purported to suppress symptoms faster than
conventional doses, leading to decreased length
of hospitalization and to few, if any, adverse
reactions (Oldham & Bott, 1971; Sangiovanni
et al. 1973; Ayd, 1977).
Although most of the subsequent randomized
control trials (RCTs) have not supported the
greater advantage of high-dose regimens over
conventional ones, high-dose regimens are still
widely used in clinical practice (Baldessarini
et al. 1984; Bollini et al. 1984; Magno Zito et al.
1987; Holloway, 1988; Reardon et al. 1989).
Unfortunately, the level of exposure to and
duration of treatment with NL drugs appear
related to the prevalence of some types of
adverse reactions, suggesting that many patients
are exposed to unnecessarily high and potentially
dangerous treatments.
The optimal maintenance dose of NL drugs
has been tested in a number of clinical studies
with reasonably similar treatment protocols.
Until now, no attempt has been made to combine
the results of clinical trials with random patient
assignment to different dose groups, or to
assess the differing quality of the trials, although
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thoughtful reviews of the field have been
published (Baldessarini et al. 1988).
Meta-analysis is a technique for combining
the results of collections of research papers to
answer specific questions, often in a quantitative
manner (Glass, 1976; Louis et al. 1985; Sacks
et al. 1987). Prompted by the need to synthesize
effectively the large body of research findings
that has progressively accumulated, and that no
longer seems adequately summarized by quali-
tative reviews, meta-analysis has been used in
several fields of medicine and public health.
Recently, the impact of NL on tardive dyskinesia
and the control of agitated demented patients
has been the object of two meta-analyses
(Morgenstern et al. 1987; Schneider et al. 1990).
We believe that a quantitative estimate of the
benefits and risks of different NL doses in
chronic schizophrenic patients is both timely
and relevant because of the widespread use of
high dose regimens, whose effectiveness and
safety have not been adequately assessed.
Therefore, we have designed the present study
to answer two questions: (1) are higher doses of
NL drugs for maintenance treatment of psy-
chosis any more effective than lower doses?; (2)
are higher doses safer?
METHOD
We searched the MEDLINE database, from
1966 to June 1989, and other sources (review
articles, reference lists from other papers), to
find all the published RCTs that compared
different doses of the same NL drug (when two
or more papers reported the same study, the
most recent version was chosen). To be selected
for the meta-analysis, papers had to satisfy the
following six criteria:
1. maintenance treatment of psychotic dis-
orders (excluding treatment of the acute
phase);
2. adult patients (older than 16 years);
3. random assignment of patients to treat-
ment;
4. availability of conversion factor of studied
treatment to chlorpromazine;
5. duration of trial of at least 4 weeks;
6. English language.
A trained meta-analysis technician blinded all
articles selected by the initial screening process,
to diminish the bias in the selection of the final
papers (Sacks et al. 1987). Authors, date of
publication, journal of publication, date of
study, site of study, and all the study findings
were obliterated, and the articles re-photocopied
so that the reader could not identify them. Two
readers (M.J.O. and M.E.A.) scored the blinded
version of the articles according to criteria for
quality previously described, and determined a
quantitative estimate of quality by consensus
(Sacks et al. 1987).
We used tables devised from extensive review
of comparative RCTs and from clinical
experience (Baldessarini et al. 1980, 1988) to
convert doses of the various NL used in the
selected articles to the equivalent amount in mg
of chlorpromazine. As an approximate equiv-
alence, 25 mg of Fluphenazine enanthate or
decanoate every 2-3 weeks was converted to a
daily oral dose of 500 mg of chlorpromazine.
For Flupenthixol decanoate, 18 mg every 2
weeks was converted to a daily oral dose of
225 mg of chlorpromazine. This procedure en-
abled us to obtain comparable doses across
studies. All but three studies considered two
doses of a chosen NL; when more than two
doses of the same NL were used, we considered
only the highest and the lowest in the analysis.
We examined clinical effectiveness and occur-
rence of side effects as the main endpoints.
In an attempt to provide a post-hoc analysis
by intention to treat, we identified three broad
categories of drop-outs from the papers: (1) lack
of symptomatic control; (2) presence of severe
adverse reactions; and (3) other reasons (e.g.
intercurrent illnesses, transfer to other wards,
lack of compliance, and discharge from the
hospital). For each of the outcomes of interest,
patients who dropped out for lack of symp-
tomatic control or adverse reactions have been
reconsidered for the present meta-analysis as
described in the following sections.
Clinical effectiveness
Each study defined improvement either as a
rating on a clinical global impression scale, or as
no psychotic relapse, or as no rehospitalization.
The three measures point in the same direction
and are consistent expressions of positive out-
come. With either of these definitions, each
study expressed the outcome of the study group
as a proportion of improved patients. For the
purpose of the meta-analysis, we considered
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patients who had dropped out of a study because
of lack of symptomatic control as not improved.
Side effects
Side effects were the second main endpoint that
we considered in the analysis. Seven studies did
not mention side-effects, and five reported them
in such a way that their data could not be
combined because only the average scores of
specific scales were reported. Therefore, we
extracted data on side-effects from only 10
studies. We have analysed adverse reactions in
three different ways: (1) any; (2) neurological
(i.e. acute dystonia, akathisia, tardive dyskinesia,
and Parkinsonism); and (3) Parkinsonism alone.
For the purpose of the meta-analysis, we counted
patients dropping out because of adverse
reactions among those with side-effects.
Statistical analysis
For each treatment arm we computed the
following summary statistics: (1) proportion of
improvement, defined as the number of patients
who had improved divided by the number of
patients who completed the study plus those
who dropped out because of lack of symptomatic
control; (2) average number of adverse reactions
per patient, defined as the total number of
adverse reactions (including those experienced
by patients who dropped out because of side
effects) divided by the number of patients who
completed the study plus those who dropped out
because of side effects; (3) average number of
neurological adverse reactions (i.e. acute dys-
tonia, akathisia, tardive dyskinesia, and Parkin-
sonism), defined as the total number of neuro-
logical adverse reactions divided by the total
number of patients (as defined above); and (4)
proportion of Parkinsonism, defined as the
number of patients who had experienced Parkin-
sonism divided by the total number of patients
(as defined above).
In an attempt to describe the dose-response
relationship, we conducted an analysis in which
each treatment arm constituted the sampling
unit. For this analysis, we considered each of the
above quantities in turn as the dependent
variable and assessed its relationship with the
independent variable, NL dose used in each arm
of each study, by means of a covariance model.
In order to avoid the assumption of a linear
dose-response model, which is not appropriate
in modeling the dose-effect relationship for
NL, we considered four dose levels, dividing
the treatment arms into four groups of equal
size, according to the observed quartiles of
administered dose: 25-165 mg, 166-375 mg,
376-830 mg, > 830 mg. We treated dose level
and study as categorical variables. We have
defined a dummy variable for the first three levels
of dose, thus considering the highest level as
reference. The model also included a random
effect for study, which permits adjustment for
between study variation and also allows for the
correlation between observations pertaining to
the same study. In order to account for the
different precision of the summary statistics
provided by each treatment arm, we weighted
the analysis by the corresponding sample size.
Appropriateness of the linear models was
assessed by analysis of residuals, and statistical
significance was tested by appropriate F tests.
No adjustments of P values for multiple com-
parisons have been considered.
RESULTS
From the above sources, we identified and
blinded a total of 30 potentially acceptable
studies. Of these, we excluded 8 studies for two
reasons: (1) four because they were cross-over
studies, with data not separable by arm (Faleni,
1970; de Buck, 1972; Deneker etal. 1978; Wiles,
1980); and (2) four because their data on
effectiveness could not be extracted (Brotman
et al. 1969; Clark et al. 1970; Chouinard &
Annable, 1976; McCreadie et al. 1979). Thus,
we included in the analysis a total of 22 RCTs
comparing two doses of the same NL drug as
maintenance treatment of chronic psychosis.
Two of these studies were originally designed to
evaluate two doses of each of three different NL
drugs: thus, for the purpose of further analyses,
we have considered a total of 20 + 6 = 26
sampling units.
The main characteristics of the selected studies
are shown in Table 1. The studies with one or
more pairs of treatment arms, one at a lower and
one at a higher dose, as defined by the
investigators, generated a collection of 52 treat-
ment groups. A total of 1638 patients were
considered, 833 in the lower dose category and
805 in the higher dose category. Almost in-
variably, patients had a diagnosis of schizo-
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S003329170002729X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 10:08:14, subject to the Cambridge Core terms of use, available at
310 P. Bollini and others
Table 1. Randomized Control Trials comparing high and low neuroleptic treatment as maintenance
in chronic psychosis
Study
Caffey et al.
1964
Prien and Cole,
1968
Simpson et al.
1968
Williams et al.
1969
Williams el al.
1969
Williams et al.
1969
Prien et al.
1969
Gardos et al.
1974
Quitkin el al.
1975
Chien, 1975
McClelland et al.
1976
Clark et al.
1977
Goldstein et al.
1978
Bjorndal et al.
1980
Branchey et al.
1981
Kane el al.
1983
Nishikawa et al.
1984
Nishikawa et al.
1985
Nishikawa et al.
1985
Nishikawa et al.
1985
Marder et al.
1987
Carpenter el al.
1987f
Johnson el al.
1987
Huang et al.
1987
Cookson,
1987
Hogarty et al.
1988
Setting
(I/O)*
I
I
I
I
I
I
I
I
I
0
I
1
o
I
I
0
o
0
0
o
0
0
0
I
I
o
Length
(weeks)
16
24
16
24
24
24
24
16
6
52
24
12
6
12
42
52
52
52
52
52
104
104
52
9
44
104
Type of NL
Phenothiazines
Chlorpromazine
Butaperazine
Fluphenazine HC1
Trifluopromazine
Trifluopromazine
+ Fluphenazine
Trifluoperazine
Thiotixene
Fluphenazine HC1
Fluphenazine
enanthate
Fluphenazine
decanoate
Loxapine
Fluphenazine
enanthate
Haloperidol
Loxapine
Fluphenazine
decanoate
Haloperidol
Thioridazine
Pimozide
Pimozide+
Thioridazine
Fluphenazine
decanoate
Various
Flupenthixol
decanoate
Thiotixene
Flupenthixol
decanoate
Fluphenazine
decanoate
CPZ/eq.
daily dose
(mg)
160
375
300
1888
263
1450
250
500
165
330
415
830
375
2000
250
1000
950
39000
258
795
500
10000
472
931
125
500
552
6210
160
664
50
500
45
270
25
75
100
300
125
375
100
500
196
720
150
225
1500
6781
1475
4163
76
500
No. of patients
Analysed
89
88
215
201
6
6
6
4
6
4
7
9
105
113
18
19
13
18
16
16
25
24
11
12
45
51
11
12
22
11
62
64
12
11
11
7
10
8
9
5
33
25
14
12
28
31
20
20
9
9
30
25
Improved
76
84
34
52
1
0
6
4
2
1
1
8
26
26
4
4
9
4
10
14
6
9
5
8
38
48
6
5
6
9
36
61
3
6
0
1
0
3
6
5
25
22
7
5
19
28
4
13
6
8
21
19
* I = In-patients; O = Out-patients.
t Involved continuous versus targeted neuroleptic treatment.
phrenia with a chronic clinical course. Studies
conducted before 1980 often dealt with in-
patients (10 out of 12), while after 1980 most
studies involved out-patients (7 out of 10),
mirroring the shift of care from the mental
hospital to community settings. Sixteen studies
were conducted in the US, three in the UK, two
in Japan and one in Denmark. Study length
varied from 6 to 104 weeks, with an average of
38-5 weeks ( + S.D. 31-3 weeks). In five studies
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Table 2. Results of the regression of clinical
effectiveness (proportion of patients improved) on
neuroleptic dose levels, corrected for study effect
Clinical
effectiveness
Dose level (mg)
=S 165
166-375
376-830
S 831
B*
-0-226
- 0 0 5 8
- 0 0 0 4
S.E. (B)
00797
00501
00839
P
0009
0-256
0-961
Ftest for regression with dose and study: F = 10-93;
d f = 28,23; P< 00001.
F test for dose, after inclusion of study: F = 5-08;
d f=3 ,23 ; /> = 0-008.
* Estimated regression coefficient.
drug-resistant patients (i.e. patients who pre-
viously did not respond to rather high NL
regimens administered from 6 weeks to more
than 2 years) were recruited. Finally, eight
studies used fixed doses (Simpson et al. 1968;
Prien et al. 1969; Williams et al. 1969; Gardos
et al. 1974; Quitkin et al. 1975; McClelland et al.
1976; Nishikawa et al. 1985, 1985; Huang et al.
1987), and the remaining flexible doses.
Lower doses, as defined by the investigators,
ranged from 25-1500 mg chlorpromazine equi-
valent, with an average of 348 mg ( + s.D.
391 mg). Higher doses, similarly defined by the
investigators, spread from 75-39000 mg, with
an average of 3110 mg ( ± S . D . 7712 mg). Al-
though the dose of 39000 mg was a definite
outlier, out of 52 treatment groups daily doses
of 1000 mg and above were tested eleven times,
four of which above 6000 mg. The year of
publication of the selected studies went from
1964 to 1987. The doses of neuroleptics tested
did not show any appreciable change over time.
The average low dose administered in trials
conducted before 1980 was 345 mg, and after
1980 350 mg. Similarly, the average high dose
tested before 1980 was 1717 mg (excluding the
study of Quitkin et al. 1975, having a high dose
of 39000 mg), and 1637 mg thereafter.
We explored the association between NL dose
and clinical effectiveness and side-effects, re-
spectively, by means of a linear regression model.
Possible differences among studies (in terms of
patient sex, age, type of setting, etc.) were taken
into account by introducing a term for each
study in the regression, and we weighted the
analysis by sample size. Thereafter, coefficients
for dose given in subsequent sections have to be
considered as adjusted for possible differences of
baselines among studies.
Regression for clinical effectiveness
We regressed the proportion of improvement
on dose groups (25—165 mg, 166-375 mg, 376-
830 mg, > 830 mg) and study as described in the
Table 3. Number and type of adverse reactions reported in 10 studies for low and high
chlorpromazine dose
Study
Gardos el al.
1974
Prien & Cole
1968
Quitkin el al.
1975
McClelland et al.
1976
Prien et al.
1969
Hogarty et al.
1988
Simpson et al.
1968
Bjorndal el al.
1980
Clark et al.
1977
Huang el al.
1987
CPZ dose
(mg)
250
1000
300
1888
950
39000
500
10000
375
2000
76
500
263
1450
552
6210
472
931
1500
6781
Acute
dyst.
0
0
2
19
0
0
0
1
11
29
0
0
1
5
0
0
0
1
9
12
Parkin-
sonism
4
9
17
39
0
7
5
8
12
56
0
0
4
6
1
3
5
5
4
6
Akathisia
5
10
19
19
0
0
2
5
14
39
0
0
0
0
1
3
1
2
3
0
Tardive
dyskin.
0
0
0
0
0
0
2
5
0
0
4
7
0
0
2
0
0
1
0
0
Hypo-
tension
0
0
2
4
0
0
0
0
21
15
0
0
0
0
0
0
3
1
3
4
Seizures
0
0
2
12
0
0
2
0
0
1
0
0
0
0
0
1
0
0
0
0
Over-
sedation
0
0
31
79
0
0
0
0
6
14
0
0
0
0
0
5
6
9
7
12
Skin
reactions
0
0
6
60
0
0
0
0
6
6
0
0
0
0
0
0
0
0
0
0
Other
6
4
66
215
0
7
0
1
36
42
0
0
0
0
0
0
3
9
1
8
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Method section. The value of the overall test for
the significance of the regression was 10-93, 28
and 23 df, P < 00001. The partial Ftest for the
terms for dose, when the terms for study were in
the model, was F = 508, 3 and 23 df, P < 0-01.
The estimated coefficients for the four dose
levels are shown in Table 2. This Table must be
interpreted considering the coding system we
have adopted for dose category. For instance,
the coefficient for the lowest dose level tells how
the prediction is affected by changing the dose
from the highest to the lowest level. The
coefficients for the other two intermediate dose
levels should be interpreted in a similar way.
Thus, the highest dose level is always taken as
the reference, and its coefficient is set to zero by
default.
The only statistically significant coefficient is
the one for the lowest dose group (b = — 0-226,
S.E. (b) = 0080, P < 0-01). Because the depen-
dent variable indicates the percentage of im-
proved patients, the interpretation of this coeffi-
cient is that on average the percentage of
improved patients in the lowest dose group was
22-6 percentage points lower than in the highest
dose group, and significantly so. For the other 2
dose groups (166-375 mg and 376-830 mg), the
associated reduction in percentage of improved
patients was 5-8 (P = 0-256) and 0-4 (P = 0-961)
percentage points respectively as compared to
the percentage of improved patients in the
highest dose category. In other words, for doses
beyond the range 166-375 mg, no significant
increases in effect could be detected as compared
to the highest dose group. On average, the same
percentage of improved patients was found at
doses in the ranges 166-375 mg, 376-830 mg,
and > 830 mg.
Regression for side effects
Ten studies reported adverse reactions in a way
suitable for data extraction, as shown in Table 3.
Parkinsonism was the single most reported
adverse reaction (191 cases in both dose groups,
corresponding to 20 % of the cases), followed by
oversedation (18%), akathisia (13%) and acute
dystonia (9%). A total of 21 cases of tardive
dyskinesia were reported, corresponding to 2 %
of the patients considered. With the exception
of hypotension, adverse reactions were more
frequent in the higher dose group, as defined by
the investigators.
Table 4. Results of the regression of side-effects
(average number per patient) on neuroleptic dose
levels, corrected for study effect
Parkinsonism
Dose level (mg)
O 7 5
376-830
^831
B*
- 0 1 8 1
- 0 1 2 4
—
S.E. (B)
00564
01285
—
P
0-0126
0-3635
—
F test for regression with dose and study: F= 3-20;
d f = 11,8 ;/> = 0055.
Partial F test for dose
F= 5-24; d f = 2 ,8 ; P ••
level, after inclusion of study:
= 0035
Neurological side-effectst
Dose level (mg)
$375
376-830
* 831
-0-359
-0-262
—
01040
0-2372
—
F test for regression with dose and study: F =
d f = 11,8; /> = 0033.
Partial F test for dose
F = 6-12; d f = 2,8;/>;
All side-effects
Dose level (mg)
O 7 5
376-830
> 831
00086
0-3013
—
= 3-83;
level, after inclusion of study:
= 00024.
-1-009
-0-739
01038
0-2365
—
00001
00142
F test for regression with dose and study: F = 21-30;
d f = 11,8; P< 00001.
Partial Ftest for dose level, after inclusion of study;
F = 48-58; df = 2,8; P < 00001.
* Estimated regression coefficient.
f Including acute dystonia, akathisia, tardive dyskinesia,
Parkinsonism.
The association between NL dose and adverse
reactions was explored by means of a linear
regression model described in the Method
section, having as dependent variable at a time
the proportion of Parkinsonism, the average
number of neurological adverse reactions (i.e.
acute dystonia, akathisia, tardive dyskinesia,
and Parkinsonism), and the average number of
adverse reactions of any kind. For consistency,
the same categories of dose level were considered
in this regression as in the analysis of clinical
effectiveness. However, because only 10 studies
reported side effects in a way suitable for data
extraction, the sparseness of the data has
required lumping together the first two cate-
gories of dose. Table 4 summarizes the results of
the analysis. For the three groups of side effects,
the F tests for the regression were always
significant, as were the F tests for the effect of
dose after inclusion of the terms for study. On
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Table 5. Some key criteria for quality
assessment
Criteria
Selection description
Therapeutic regimen definition
Blinding of observers
Blinding of randomization process
Prior estimate of sample size
Reporting of withdrawals
Handling of withdrawals
Reporting of side effects
Maximum
score
possible
3
3
8
10
3
4
4
3
% Achieving
maximum
score
(A? = 22)
64
36
27
5
0
36
9
27
average, after adjustment for study, the per-
centage of patients with Parkinsonism, as pre-
dicted by the model, was 18 percentage points
(P = 00126) less in the lowest dose category
(^ 375 mg) than in the highest dose category
($5 831 mg). The same patients experienced on
average 0-359 (P = 0-0086) fewer neurological
adverse reactions and 1009 fewer adverse
reactions of any kind (P = 00001). For
the latter endpoint, a significant reduction
(b = -0-739,/5 = 0-0142) was observed also in the
intermediate dose group (376-830 mg).
Quality scoring
The mean quality score of the 22 selected papers
was 0-32 (±s.D. 0-11). Table 5 shows the
percentage of articles that achieved the maxi-
mum score possible on eight criteria we judged
to be particularly important for studies of high-
and low-dose NL. Overall, only the reporting of
the selection of the study patients was satis-
factory, while the reporting of the calculation
of the sample size, the blinding of randomization
process, the handling of withdrawals in the
analysis and the reporting of side-effects received
the lowest quality score.
DISCUSSION
Meta-analysis is a quantitative approach to the
review and synthesis of a number of research
papers addressing the same research issue.
Because clinical studies are often conceived
differently, and often report information dif-
ferently, meta-analysis summarizes simple data
on treatment and major endpoints. For this
reason, it usually answers research questions
more sharply defined than the ones of the
original collection of studies (Louis et al. 1985).
Meta-analysis is helpful in the following ways:
(1) increase statistical power for major endpoints
and subgroup analyses; (2) help resolve un-
certainty when reports disagree; (3) improve
estimates of effect size; and (4) answer questions
not posed at the start of individual trials (Sacks
et al. 1987).
In the present study, we used meta-analysis to
approach in a quantitative way the issue of the
best maintenance NL dose in chronic psychosis.
Drug utilization studies using mean chlorpro-
mazine equivalent doses showed that high doses
are still frequently used (Baldessarini et al. 1984;
Bollini et al. 1984; Magno Zito et al. 1987;
Holloway, 1988). One report indicated that the
average dose administered has increased over
the years (Reardon et al. 1989). Randomized
control trials comparing different NL doses
provided controversial results. With these prem-
ises, we felt that a quantitative overview could
provide an objective synthesis of the available
evidence.
In particular, using multiple regression we
were able to evaluate clinical effectiveness and
adverse reactions at different doses. Introducing
a term for each study in the model allowed us to
take into account different study characteristics
(for instance, patient's age and sex, drug re-
sistance status, therapeutic setting, etc.). More-
over, we weighted the regression according to
study size, in order to account for the different
variability of the estimates of the effect.
The present meta-analysis of higher versus
lower dose maintenance treatment of chronic
psychosis gave the following answers to our
original questions: (1) there is no therapeutic
advantage to be gained beyond the dose range
between 166 and 375 mg equivalent of chlor-
promazine; and (2) adverse reactions increase
significantly above these doses.
Our results suggest that, on average, a dose up
to 165 mg equivalent is significantly less effective
as compared with the reference category of
more than 830 mg. However, no significant
therapeutic advantage is found above 375 mg
equivalent of chlorpromazine. Of course, dose
equivalence is an imperfect measure of NL dose,
but the range of lowest effective dose that we
have obtained is very similar to the figure of
300 mg equivalent of chlorpromazine identified
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in the analysis of 23 clinical trials as the threshold
dose for effectiveness, beyond which clinical
advantages may not be found regularly (Baldes-
sarini & Davis, 1980).
The apparent lack of incremental benefit with
increase in NL dose might have been caused by
an increase in frequency and severity of adverse
reactions that affect behaviour. It is well known
in fact that some dose-dependent side effects of
NL drugs, such as Parkinsonism, over-sedation
and akathisia, could easily be confused with
clinical manifestations of psychosis (Quitkin
et al. 1975; Bollini et al. 1984). Accordingly, a
patient with Parkinsonism or oversedation may
be considered withdrawn or depressed, or one
with akathisia may be seen as agitated. Con-
sistently with this hypothesis, both neurological
and overall side effects were significantly
increased with higher doses.
About one-third (7 out of 22) of the trials did
not mention side effects, although they were
probably present in all studies, and only 27 % of
the papers that reported side effects did so in a
complete and accurate way. Side effects are
often inadequately reported in clinical studies.
Venulet and colleagues (1982), in a review of
quality and completeness of articles on adverse
drug reactions published between 1972 and
1979, observed that only 19% reported them
adequately. Moreover, RCTs usually select
patients in order to maximize the treatment
difference they want to show. This selection,
which is totally legitimate, often leads to the
exclusion of patients more prone to side effects.
These two reasons, inadequate reporting of side
effects and selection of patients, probably led to
incidence figures lower than the ones usually
found in epidemiological studies.
The small number of studies included in the
meta-analysis reporting adverse reactions un-
fortunately reduced the sample size for these
analyses, and did not allow the study of each
side effect separately, except for Parkinsonism.
Neurological side effects, as expected, were the
most common problem reported, in particular
Parkinsonism and akathisia. Few incident cases
of tardive dyskinesia were reported, a proportion
of 002 and 003 in the lower and higher dose
group respectively, as defined by the investi-
gators. However, most of the patients had
already been exposed to chronic NL treatment,
and thus a number of them had already acquired
tardive dyskinesia. Overall, patients receiving
more than 375 mg equivalent of chlorpromazine
showed a significantly higher occurrence of
both Parkinsonism and neurological adverse
reactions. It is worth noting that neurological
adverse effects, and Parkinsonism in particular,
might severely limit patients' social functioning.
The studies examined achieved an average
quality score of 0-32. This compares with a mean
score of 0-42 for a sample of 376 trials published
between 1949 and 1986 in 18 subject areas
examined by Reitman and colleagues (1987).
However, none of the trials scored was from the
psychiatric literature, making a quality com-
parison difficult. None of the trials included in
the present meta-analysis reported a calculation
of sample size before start of the study.
Furthermore, only 8 % of the studies handled
drop-outs satisfactorily, although early inter-
ruption of treatment due to both worsening of
clinical state and adverse reactions are likely to
differ by treatment. Our decision to include the
first in the category with known outcome, and
the latter among adverse reactions is the best
approximation to an adequate statistical hand-
ling of dropouts. In his review of design and
analysis of psychopharmacology research, Gold-
berg (1987) acknowledged handling of dropouts
and sample size requirements among the issues
still in need of improvement.
Finally, we should mention that the present
meta-analysis dealt only with published RCTs in
English. The scope of the meta-analytical effort
was initially to cover all literature on the topic,
irrespective of language. During the initial phase
of literature search, the authors realized that
invariably publications in languages different
from English did not meet the methodological
standards to be eventually included in the
overview. This is not to be interpreted as poor
quality of research in non-English speaking
countries, but rather as a reflection of the more
stringent peer review system in journals pub-
lished in English. At that stage, no further
evaluation of non-English literature was per-
formed.
Previous researchers have argued that un-
published results might importantly affect meta-
analysis conclusions, insofar as studies with
positive results are more likely to be published
than studies with negative results (Begg & Berlin,
1989), although publication bias seems greater
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in observational and laboratory-based exper-
imental studies than in randomized clinical trials
(Easterbrook et al. 1991). This point is of course
very difficult to prove, because the results of
unpublished studies are usually unavailable. In
our case, we can only speculate that, since higher
doses constituted the 'innovative' treatment,
it is more likely that trials reaching results
unfavourable to higher doses may not have been
published. If this were so, then published studies
would over-represent studies favouring 'effec-
tive ' high doses: the results of the present meta-
analysis would thus be biased downwards.
CONCLUSION
The results of the present meta-analysis support
the view that moderate doses of NL drugs
(roughly between 165 and 375 mg equivalent of
chlorpromazine) should be preferred in the
maintenance treatment of chronic psychosis.
Higher doses fail to produce incremental
improvement but significantly increase the
occurrence of adverse reactions. Neuroleptic
drugs have proven to be a crucial therapeutic
tool in the treatment of psychosis. This does not
imply that all patients should receive NL drugs,
or drug treatment alone (Karon, 1989). Quanti-
tative evidence from meta-analysis suggests that,
when pharmacological treatment is deemed
necessary for chronic schizophrenic patients, the
optimal balance between clinical effectiveness
and adverse reactions is found in the low to
moderate dose range.
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